FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(The FASEB Journal. 2008;22:1076.18)
© 2008 FASEB
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Abe, F.
Right arrow Articles by Talmadge, J. E.
PubMed
Right arrow Articles by Abe, F.
Right arrow Articles by Talmadge, J. E.
(The FASEB Journal. 2008;22:1076.18.)
© 2008 FASEB

1076.18

Chemopreventative activity of a cyclooxygenase-2 inhibitor in FBV transgenic mice with a CMV promoter driven MMTV/neu transgene

Fuminori Abe1, Moses Donkor1, Eric Scholar2, Alicia Dafferner1, Sherry Westphal1, Traci Hoke1 and James E. Talmadge1

1 Pathology & Microbiology
2 Pharmacology & Exp Neuroscience, University of Nebraska Medical Center, Omaha, NE

ABSTRACT

We have previously examined the effect of transplantable, murine mammary tumor growth on the expansion of myeloid-derived suppressor cells (MDSCs) and their tumor infiltration, as well as the relationship of MDSC frequency to T cells. We report an extension of these studies using mouse mammary tumor virus (MMTV) promoter driven HER2/Neu proto-oncogene transgenic, FBV mice (neu transgenic mice). Studies in this model also included an assessment of the tumor chemopreventative activity by the cyclooxygenase-2 inhibitor, celecoxib (80 mg/kg in drinking water). We report that celecoxib administration delayed tumor induction, increased the incidence of apoptotic tumor cells in the treated mice, and prolonged survival. In addition, immune surrogates in the spleens and tumors were studied by flow cytometry and quantitative reverse transcriptase polymerase chain reaction analysis. These studies revealed that tumor development expanded MDSCs numbers and depressed the T cell frequency in the spleen. Celecoxib administration reduced the MDSC expansion and T cell depression in the spleen and tumors. The tumor associated increase in transcript levels of COX-2, G-CSF, GM-CSF TGF-β, NOS-2, ARG-1 and VEGF-{alpha} were reduced by celecoxib administration. The greatest increase in cytokine and enzyme levels were observed within tumor infiltrating leukocytes relative to spleen cells, suggesting a tumor-immune cell interaction.

Supported in part by funding from NIH grant 5 RO1 AT001739, Eppley Cancer Center and Nebraska DHHS LB506.





This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Abe, F.
Right arrow Articles by Talmadge, J. E.
PubMed
Right arrow Articles by Abe, F.
Right arrow Articles by Talmadge, J. E.